scholarly journals Suction Curettage and Foley Balloon as a First-Line Treatment Option for Caesarean Scar Pregnancy and Reproductive Outcomes

2021 ◽  
Vol Volume 13 ◽  
pp. 239-245
Author(s):  
Melike Aslan ◽  
Şeyda Yavuzkir
Keyword(s):  
Treatment Option ◽  
Line Treatment ◽  
Reproductive Outcomes ◽  
First Line ◽  
Caesarean Scar ◽  
Suction Curettage ◽  
Caesarean Scar Pregnancy ◽  
First Line Treatment

scholarly journals Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia

2018 ◽  
Vol 16 ◽  
pp. 74-80 ◽  
Author(s):  
Gabriel Tremblay ◽  
Vasiliki Chounta ◽  
James Piercy ◽  
Tim Holbrook ◽  
Shan Ashton Garib ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Treatment Option ◽  
Line Treatment ◽  
First Line ◽  
Treatment Naïve ◽  
Hiv 1 ◽  
First Line Treatment

scholarly journals Lacosamide As First Line Treatment Option In Focal Epilepsy; A Cost-Utility Analysis for The Greek Healthcare System

2017 ◽  
Vol 20 (9) ◽  
pp. A724
Author(s):  
M Geitona ◽  
E Stamuli ◽  
S Giannakodimos ◽  
V Kimiskidis ◽  
V Kountouris ◽  
...  
Keyword(s):  
Healthcare System ◽  
Treatment Option ◽  
Focal Epilepsy ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Line Treatment ◽  
Utility Analysis ◽  
First Line ◽  
First Line Treatment

scholarly journals Can endovascular repair be the first-line treatment option in abdominal aortic aneurysms during COVID-19 pandemic?

2021 ◽  
Vol 30 (2) ◽  
pp. 107-114
Author(s):  
Kaptanıderya Tayfur ◽  
Melih Ürkmez
Keyword(s):  
Treatment Option ◽  
Abdominal Aortic Aneurysms ◽  
Aortic Aneurysms ◽  
Line Treatment ◽  
Rt Pcr ◽  
First Line ◽  
Abdominal Aortic ◽  
Significant Difference ◽  
The Mean ◽  
First Line Treatment

Objectives: This study aims to investigate the effectiveness of endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs) during the novel coronavirus-2019 (COVID-19) pandemic. Patients and methods: A total of 22 patients (17 males, 5 females; mean age: 76.7±7.1 years; range, 66 to 90 years) who underwent EVAR for AAAs in our center between March 2020 and December 2020 were retrospectively analyzed. All patients underwent reverse transcriptase- polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. All EVAR procedures were performed under spinal anesthesia in the elective setting in the angiography laboratory. Results: The RT-PCR test result was positive in six patients with asymptomatic infection. The mean AAA diameter was 74.7±5.5 (range, 68.50 to 85.60) mm. Stent-graft implantation was successfully performed in all patients. There was no significant relationship between the mean age and examined variables (p>0.050). The mean AAA diameter was 83.95 mm in the COVID-19-positive patients and 71.50 mm in the COVID-19-negative patients, indicating a significant difference (p=0.001). No mortality, stent migration or thrombotic events were observed during the first 30 days of follow-up. Conclusion: The operation can be delayed in patients requiring open surgical repair or in those with small AAAs. Based on our findings, the EVAR can be used as the first-line treatment option during the pandemic, as it does not require intubation and requires a low number of staff and is cost-effective with minimum necessity for intensive care unit stay and less use of healthcare resources.

scholarly journals DOP54 Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S089-S090
Author(s):  
A Rezazadeh Ardabili ◽  
S F G Jeuring ◽  
Z Mujagic ◽  
M J L Romberg-Camps ◽  
A A van Bodegraven ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Maintenance Therapy ◽  
Treatment Option ◽  
Real World ◽  
Population Based ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Abstract Background In current guidelines, thiopurines are still recommended as first-line maintenance therapy for patients with Crohn’s disease (CD). Due to their lack of immunogenicity, oral administration route and low costs, thiopurines are an attractive first-line treatment option. However, in recent studies the position of thiopurine monotherapy in CD has been questioned as a result of relatively lower overall effectiveness rates compared to ulcerative colitis. Real-world long-term effectiveness data substantiating the use and position of thiopurines in CD management remain sparse. We assessed long-term effectiveness of thiopurine monotherapy in CD using the population-based IBD South-Limburg (IBDSL) cohort. Methods All CD patients in the IBDSL cohort starting thiopurine monotherapy as first-line maintenance therapy between 1991–2014 were included. Thiopurine monotherapy was defined effective if either: (1) no escalation to biological treatment, (2) no course of corticosteroids, (3) no resective surgery or, (4) no hospitalization for active disease was required whilst on thiopurine treatment. Patients with early treatment discontinuation (i.e. <3 months) were identified, including reason of discontinuation. Long-term effectiveness was assessed adjusting for differences in follow-up between patients using Kaplan-Meier analysis. Potential risk factors for therapy failure were identified using Cox regression. Results In total, 643/1162 (55.3%) CD patients (median follow-up: 8.5 years IQR 5.0–13.2) received first-line thiopurine monotherapy after a median of 9.7 months (IQR 3.2–31.3) after diagnosis. Therapy was discontinued within three months in 164 patients (25.5%), mainly due to adverse events [Figure 1]. Thiopurine monotherapy was effective for the duration of treatment in 229/479 (35.6%) patients, corresponding to estimated effectiveness rates of 62.9%, 43.9% and 31.2% after 1, 5 and 10 years, respectively [Figure 1–2]. No significant difference in effectiveness was observed after stratifying for era of thiopurine initiation (pre-biological (1991–1998) vs. biological (>1999) era, p=0.84). Factors associated with thiopurine failure were stricturing disease (aHR 1.41, 95%CI 1.01–1.96) and upper GI involvement (aHR 1.52, 95%CI 1.02–2.28) at diagnosis. During follow-up, 40/229 patients with a durable response discontinued treatment due to quiescent disease. Of these, 35 patients (87.5%) remained without treatment 24 months after discontinuation. Conclusion Real-world data from this population-based study demonstrate that thiopurine monotherapy remains an effective and durable first-line treatment option for CD, even in the biological era. These results should be considered in the ongoing discussion regarding the position of thiopurine therapy.

Sign in / Sign up

Export Citation Format

Share Document